RhumbLine Advisers’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-16,600
| Closed | -$33.7K | – | 4141 |
|
|
2025
Q1 | $33.7K | Sell |
16,600
-1,155
| -7% | -$2.34K | ﹤0.01% | 3655 |
|
|
2024
Q4 | $107K | Sell |
17,755
-5
| -0% | -$30 | ﹤0.01% | 3460 |
|
|
2024
Q3 | $124K | Buy |
17,760
+1,551
| +10% | +$10.9K | ﹤0.01% | 3442 |
|
|
2024
Q2 | $94K | Buy |
16,209
+5,320
| +49% | +$30.9K | ﹤0.01% | 3530 |
|
|
2024
Q1 | $77.8K | Buy |
10,889
+1,619
| +17% | +$11.6K | ﹤0.01% | 3521 |
|
|
2023
Q4 | $45.6K | Sell |
9,270
-207
| -2% | -$1.02K | ﹤0.01% | 3647 |
|
|
2023
Q3 | $90.6K | Buy |
9,477
+491
| +5% | +$4.69K | ﹤0.01% | 3495 |
|
|
2023
Q2 | $116K | Buy |
+8,986
| New | +$116K | ﹤0.01% | 3460 |
|